Bank Julius Baer & Co. Ltd Zurich lowered its position in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 91.8% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 2,084 shares of the biotechnology company's stock after selling 23,201 shares during the period. Bank Julius Baer & Co. Ltd Zurich's holdings in Arcturus Therapeutics were worth $39,000 as of its most recent filing with the SEC.
Several other institutional investors have also modified their holdings of the company. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Arcturus Therapeutics by 10.8% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,694 shares of the biotechnology company's stock valued at $202,000 after buying an additional 846 shares in the last quarter. SG Americas Securities LLC grew its position in Arcturus Therapeutics by 45.0% in the 4th quarter. SG Americas Securities LLC now owns 11,940 shares of the biotechnology company's stock valued at $203,000 after buying an additional 3,705 shares in the last quarter. Spire Wealth Management grew its position in Arcturus Therapeutics by 393.3% in the 4th quarter. Spire Wealth Management now owns 13,478 shares of the biotechnology company's stock valued at $229,000 after buying an additional 10,746 shares in the last quarter. BNP Paribas Financial Markets grew its position in Arcturus Therapeutics by 954.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 15,831 shares of the biotechnology company's stock valued at $367,000 after buying an additional 14,330 shares in the last quarter. Finally, Verition Fund Management LLC bought a new position in Arcturus Therapeutics in the 3rd quarter valued at about $420,000. Institutional investors own 94.54% of the company's stock.
Arcturus Therapeutics Trading Down 7.6 %
ARCT stock opened at $13.21 on Wednesday. Arcturus Therapeutics Holdings Inc. has a one year low of $12.75 and a one year high of $45.00. The firm has a market capitalization of $357.82 million, a PE ratio of -5.95 and a beta of 2.96. The firm has a 50-day moving average of $16.83 and a two-hundred day moving average of $18.44.
Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last posted its quarterly earnings data on Thursday, March 6th. The biotechnology company reported ($1.11) EPS for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.78). Arcturus Therapeutics had a negative net margin of 36.39% and a negative return on equity of 22.39%. The firm had revenue of $22.77 million for the quarter, compared to analysts' expectations of $44.64 million. On average, equities research analysts anticipate that Arcturus Therapeutics Holdings Inc. will post -2.22 earnings per share for the current year.
Wall Street Analyst Weigh In
A number of equities analysts recently issued reports on ARCT shares. Canaccord Genuity Group decreased their target price on shares of Arcturus Therapeutics from $74.00 to $68.00 and set a "buy" rating for the company in a research report on Monday. BTIG Research set a $48.00 target price on shares of Arcturus Therapeutics and gave the company a "buy" rating in a research report on Monday. Cantor Fitzgerald restated an "overweight" rating on shares of Arcturus Therapeutics in a research report on Friday, March 7th. HC Wainwright reduced their price objective on shares of Arcturus Therapeutics from $63.00 to $60.00 and set a "buy" rating for the company in a research report on Friday, March 7th. Finally, Wells Fargo & Company reduced their price objective on shares of Arcturus Therapeutics from $58.00 to $50.00 and set an "overweight" rating for the company in a research report on Friday, March 7th. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $59.20.
Check Out Our Latest Analysis on ARCT
About Arcturus Therapeutics
(
Free Report)
Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.
Recommended Stories
Want to see what other hedge funds are holding ARCT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Arcturus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arcturus Therapeutics wasn't on the list.
While Arcturus Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
